Protara Therapeutics, Inc. (TARA) - Rasio rega marang prakiraan pendapatan
The forward P/S ratio on the GURU.Markets chart illustrates the asset's valuation trend, with the current level sitting around . Protara Therapeutics operates within the biotechnology sector, focusing on the development of drugs for rare oncological diseases in US laboratories. The business is entirely non-cyclical and independent of GDP, while management under Jesse Shem effectively controls budgets and clinical programs.
Rincian metrik komprehensif lan analitis Protara Tx (TARA)
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- indikator nilai buku ekuitas:
- data utang lan likuiditas:
Utang marang Ekuitas Protara Therapeutics|TARA - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Protara Therapeutics|TARA - Gunggung utang perusahaan|Utang marang nilai buku Protara Tx|TARA - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Protara Therapeutics|Rasio cepet protaratx.com
- indikator pendapatan resik lan kelipatan nilai:
TARA - Bathi pungkasan|Proyeksi bathi mangsa ngarep Protara Therapeutics|TARA - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Protara|TARA - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Protara Tx|TARA - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Protara Therapeutics|TARA - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan protaratx.com|TARA - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Protara Therapeutics
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:Protara Therapeutics, Inc. (TARA)
For Protara Therapeutics (TARA), which is developing cancer therapies without any debt load, the projected P/S ratio reflects the market value relative to expected revenue. This indicator compares current market capitalization with future sales, allowing investors to determine the extent of asset overvaluation or identify an entry point by comparing current values with the company's historical lows and highs.
Pesaing wigati
Rasio rega marang prakiraan pendapatan BeiGene ONC|Rega forward marang dodolan HALO|RVMD - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ascentage Pharma Corp|CGON (CG Oncology, Inc.) - Multiplikator forward rega marang pendapatan|URGN: Rasio rega marang pendapatan sing dikarepake|BCAX (Bicara Therapeutics) - Multiplikator Forward P/S|Multiplikator Forward P/S Personalis Inc|Rasio rega marang prakiraan pendapatan Erasca Corp (ERAS)|DCTH (Delcath Corp) - Rega forward marang dodolan|Multiplikator Forward P/S YMAB (Y-mAbs Therapeutics)|Multiplikator Forward P/S aurabiosciences.com AURA|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc)|SLS (sellaslifesciences.com) - Multiplikator forward rega marang pendapatan|ACTU: Rasio rega marang pendapatan sing dikarepake|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|HURA: Rega forward marang dodolan|Multiplikator Forward P/S FATE|WHWK - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan TScan Therapeutics, Inc. TCRX|Rega forward marang dodolan CSBR|XBiotech USA - Multiplikator Forward P/S|CVM - Multiplikator Forward P/S|OS Therapies (OSTX) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan RADX (radiopharmtheranostics.com)|ARTV (Artiva Biotherapeutics Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Adlai Nortye Limited ANL|Multiplikator forward rega marang pendapatan VERU (Veru Inc.)|Multiplikator Forward P/S tempesttx.com (TPST)|Xilio Therapeutics - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake RENB (Renovaro Biosciences)|Mural Bio - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Kairos Pharma Ltd KAPA|OKUR: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan CytoMed Therapeutics Limited|Rasio rega marang prakiraan pendapatan Curis Inc.|Apollomics Corp (APLM) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan THAR (Tharimmune Corp)|Rasio rega marang pendapatan sing dikarepake ADVB|Multiplikator Forward P/S GNPX (Genprex, Inc.)|Multiplikator Forward P/S Calidi Biotherapeutics Inc. CLDI|SBFM - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan XBIO (Xenetic Biosciences)|SLRX: Multiplikator Forward P/S|Kitov Pharma (PPBT) - Multiplikator Forward P/S|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan beigene.com (BGNE)|Multiplikator Forward P/S CKPT|Multiplikator Forward P/S elevationoncology.com (ELEV)|Rasio rega marang prakiraan pendapatan iCAD ICAD|IKNA: Kapitalisasi marang prakiraan pendapatan|Notable Labs, Ltd. - Multiplikator Forward P/S|Viracta Therapeutics (VIRX) - Multiplikator forward rega marang pendapatan|MOR: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NAYA Biosciences Inc (NAYA)|Rasio rega marang prakiraan pendapatan Ascentage Pharma Group Ltd
